Bailard’s Crescent Biopharma CBIO Stock Holding History

Bailard’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-710	Closed	-$1.15M	–	525
2018 Q1	$1.15M	Buy	+710	New	+$1.48M	0.07%	206

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bailard's CBIO Position: Q2 2018 in Review

Bailard sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 710 shares — an estimated $1.15M sold.

Bailard first reported a position in CBIO in Q1 2018 and held it in 1 quarter. The position peaked at $1.15M in Q1 2018. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

Bailard reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
Bailard sold 710 Crescent Biopharma shares in Q2 2018, an estimated $1.15M.
Bailard first reported a position in Crescent Biopharma in Q1 2018 and held it in 1 quarter.
Bailard's Crescent Biopharma position peaked at $1.15M in Q1 2018.
84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on Bailard's 13F filing for Q2 2018, filed 8 Aug 2018.